The Science And Technology Award from the Human Proteome Organization recognizes an individual or team in private industry who played a key role in commercialization, and making widely available, a proteomics technology, product or procedure.

Drs. N. Leigh Anderson, Morteza Razavi and Selena Larkin were recipients of the 2015 award, based on the commercial proliferation and widespread adoption of the SISCAPA technique through efforts of the team at SISCAPA Assay Technologies (SAT).

The SISCAPA ® method facilitates highly multiplexed, high throughput quantitation of proteins via antibody capture of proteotypic peptides followed by mass spectrometry – sometimes known generically as immuno-MRM or immuno-MALDI. The patented technique has been widely adopted as a replacement for problematic immunoassays, for validation and verification of candidate biomarkers and for studying pharmacokinetics of large molecule therapeutics.

First described in 2004 and officially marketed via establishment of SAT in 2012, the SISCAPA technique is used today in research settings around the world and by licensees in pharma and CROs as well as in clinical laboratories, where it is used to deliver high-value results to tens of thousands of patients each year.

“It is a significant honor to earn this recognition from such an esteemed global organization, and to be in such superb company as past years’ recipients,” said N. Leigh Anderson, the inventor of SISCAPA and founder, Chairman and CEO of SAT. “We are confident that SISCAPA will continue to proliferate as the preferred method for longitudinal measurement of protein biomarker panels in the clinic.”

The news of this award follows the public announcement of a four-year, $2 million Grand Challenge Award from the American Heart Association to Jennifer van Eyk’s and Dan Rader’s teams to accelerate discovery of personalized treatments and prevention of cardiovascular diseases (CVD).

In the first phase of the study, large numbers of annotated blood samples from the Jackson Heart Study, the Framingham Offspring Heart Study and South Asian PROMIS study will be screened against panels of protein biomarkers using existing SISCAPA assays. Importantly, the funding provides for generation of a significant number of new SISCAPA assays against additional CVD candidate biomarkers.

“We are delighted to contribute to this important study,” said Selena Larkin, VP of Marketing and Sales at SAT. “The generation of population data across a broad panel of markers is key to developing personalized therapies. This opportunity to expand the SISCAPA assay portfolio will enable rigorous measurement of more proteins in research and in the clinic.”

Members of the SAT team will be present at the 2015 World HUPO meeting in Vancouver to participate in the program and to accept the award. The technology will also be presented that week at the Select Biosciences conference NGS, SCA, Mass Spec: The Road to Diagnostics in San Diego.